Skip to main content
. 2022 Jun 1;127(5):908–915. doi: 10.1038/s41416-022-01806-6

Fig. 3. Relationships between MRD levels measured by quantitative real-time PCR on the same DNA samples with different types of MRD markers.

Fig. 3

a ABL fusion versus Ig/TCR tests for 21 patients. All assays were patient-specific using primers and probes shown in the supplement. Samples collected from Patient 18 after an AML secondary malignancy were excluded. b BCR-ABL1 versus Ig/TCR tests for 40 patients. All assays were patient-specific. c IKZF1 versus Ig/TCR tests in nine ABL-class patients. Three different IKZF1 generic tests were used. d IKZF1 versus Ig/TCR tests in 23 BCR-ABL1 patients. Four different IKZF1 tests were used. e IKZF1 versus ABL-class tests in nine ABL-class patients. f IKZF1 versus BCR-ABL1 tests in 26 BCR-ABL1 patients.